ZSTK474, A novel PI3K inhibitor, modulates human CD14+ monocyte-derived dendritic cell functions and suppresses experimental autoimmune encephalomyelitis

Journal of Molecular Medicine

Volumn 92, Issue 10, 2014, Pages 1057-1068

  Xue, Zhenyi ^a   Li, Wen ^a   Wang, Huafeng ^a   Huang, Biao ^a   Ge, Zhenzhen ^a   Gu, Chao ^a   Liu, Ying ^b   Zhang, Kai ^a   Yang, Juhong ^a   Han, Rong ^a   Peng, Meiyu ^a   Li, Yan ^a   Zhang, Da ^a   Da, Yurong ^a   Yao, Zhi ^a   Zhang, Rongxin ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN FIRST CENTRAL HOSPITAL   (China)

Author keywords

Dendritic cells; Experimental autoimmune encephalomyelitis; Multiple sclerosis; PI3K; Th17 cells; ZSTK474

Indexed keywords

2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; ANTIINFLAMMATORY AGENT; CYTOKINE; LEUKOCYTE ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; TRIAZINE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; DENDRITIC CELL; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENDOCYTOSIS; HUMAN; IMMUNOLOGY; MONOCYTE; T LYMPHOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENDOCYTOSIS; HUMANS; MICE, INBRED C57BL; MONOCYTES; PHOSPHATIDYLINOSITOL 3-KINASES; T-LYMPHOCYTES; TRIAZINES;

EID: 84931825570     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-014-1158-x     Document Type: Article

References (34)

1. Ruckle T, Schwarz M, Rommel C (2006) PI3Kgamma inhibition: towards an ‘aspirin of the 21st century’? Nat Rev Drug Discov 5:903–918
2. Fruman DA, Cantley LC (2002) Phosphoinositide 3-kinase in immunological systems. Semin Immunol 14:7–18
3. Rommel C, Camps M, Ji H (2007) PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol 7:191–201
4. Kong D, Dan S, Yamazaki K, Yamori T (2010) Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39. Eur J Cancer 46:1111–1121
5. Hu L, Zaloudek C, Mills G, Gray J, Jaffe R (2000) In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 6:880–886
6. Ihle N, Williams R, Chow S, Chew W, Berggren M, Paine-Murrieta G, Minion D, Halter R, Wipf P, Abraham R et al (2004) Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 3:763–772
7. Yaguchi S, Fukui Y, Koshimizu I, Yoshimi H, Matsuno T, Gouda H, Hirono S, Yamazaki K, Yamori T (2006) Antitumor activity of ZSTK474: a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 98:545–556
8. Kong D, Yamori T (2007) ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms. Cancer Sci 98:1638–1642
9. Kong D, Yamori T (2008) Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci 99:1734–1740
10. Kong D, Yaguchi S, Yamori T (2009) Effect of ZSTK474: a novel phosphatidylinositol 3-kinase inhibitor on DNA-dependent protein kinase. Biol Pharm Bull 32:297–300
11. Kong D, Yamori T (2009) Advances in development of phosphatidylinositol 3-kinase inhibitors. Curr Med Chem 16:2839–2854
12. Toyama S, Tamura N, Haruta K, Karakida T, Mori S, Watanabe T, Yamori T, Takasaki Y (2010) Inhibitory effects of ZSTK474: a novel phosphoinositide 3-kinase inhibitor, on osteoclasts and collagen-induced arthritis in mice. Arthritis Res Ther 12:R92
13. Krishnamoorthy G, Wekerle HEAE (2009) An immunologist’s magic eye. Eur J Immunol 39:2031–2035
14. Loma I, Heyman R (2011) Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol 9(3):409–416
15. Hazeki K, Nigorikawa K, Hazeki O (2007) Role of phosphoinositide 3-kinase in innate immunity. Biol Pharm Bull 30:1617–1623
16. Yu Y, Nagai S, Wu H, Neish AS, Koyasu S, Gewirtz AT (2006) TLR5-mediated phosphoinositide 3-kinase activation negatively regulates flagellininduced proinflammatory gene expression. J Immunol 176:6194–6201
17. + T cells. Adv Immunol 81:331–371
18. Sakaguchi S (2004) Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531–562
19. Dittel BN (2008) CD4 T cells: balancing the coming and going of autoimmune-mediated inflammation in the CNS. Brain Behav Immun 22(4):421–430
20. Stromnes IM, Goverman JM (2006) Active induction of experimental allergic encephalomyelitis. Nat Protoc 1(4):1810–1819
21. Ge Z, Da Y, Xue Z, Zhang K, Zhuang H, Peng M, Li Y, Li W, Simard A, Hao J et al (2013) Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis. Exp Neurol 241:56–66
22. Xue Z, Ge Z, Zhang K, Sun R, Yang J, Han R, Peng M, Li Y, Li W, Zhang D et al (2014) Embelin suppresses dendritic cell functions and limits autoimmune encephalomyelitis through the TGF-β/β-catenin and STAT3 signaling pathways. Mol Neurobiol 49(2):1087–1101
23. Shakhar G, Lindquist RL, Skokos D, Dudziak D, Huang JH, Nussenzweig MC, Dustin ML (2005) Stable T cell-dendritic cell interactions precede the development of both tolerance and immunity in vivo. Nat Immunol 6:707–714
24. Del Prete A, Vermi W, Dander E, Otero K, Barberis L, Luini W, Bernasconi S, Sironi M, Santoro A, Garlanda C et al (2004) Defective dendritic cell migration and activation of adaptive immunity in PI3Kgamma-deficient mice. EMBO J 23:3505–3515
25. Haylock-Jacobs S, Comerford I, Bunting M, Kara E, Townley S, Klingler-Hoffmann M, Vanhaesebroeck B, Puri KD, McColl SR (2011) PI3Kδ drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cellapoptosis and promoting Th17 differentiation. J Autoimmun 36(3–4):278–287
26. Berod L, Heinemann C, Heink S, Escher A, Stadelmann C, Drube S, Wetzker R, Norgauer J, Kamradt T (2011) PI3Kgamma deficiency delays the onset of experimental autoimmune encephalomyelitis and ameliorates its clinical outcome. Eur J Immunol 41(3):833–844
27. Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E, Pearce W, Meek SE, Salpekar A, Waterfield MD et al (2002) Impaired B and T cell antigen receptor signaling in p110δ PI 3-kinase mutant mice. Science 297:1031–1034
28. Okkenhaug K, Patton DT, Bilancio A, Garçon F, Rowan WC, Vanhaesebroeck B (2006) The p110δ isoform of PI3K controls clonal expansion and differentiation of T helper cells. J Immunol 177(8):5122–5128
29. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K et al (2000) Novel p19 protein engages IL-12p40 to form a cytokine IL-23 with biological activities similar as well as distinct from IL-12. Immunity 13:715–725
30. Yaldizli O, Putzki N (2009) Natalizumab in the treatment of multiple sclerosis. Ther Adv Neurol Disord 2(2):115–128
31. Cox AL, Thompson SA, Jones JL, Robertson VH, Hale G, Waldmann H, Compston DA, Coles AJ et al (2005) Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 35:3332–3342
32. Stromnes IM, Goverman JM (2006) Passive induction of experimental allergic encephalomyelitis. Nat Protoc 1:1952–1960
33. Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KH et al (2010) T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol 162(1):1–11
34. Mills KH (2008) Induction, function and regulation of IL-17-producing T cells. Eur J Immunol 38:2636–2649